| HOME >> BIOLOGY >> TECHNOLOGY |
Release Highlights
- Melogliptin continues to demonstrate potential to be the
best-in-class in achieving glycemic control with low incidence of
hypoglycemia and neutral effect on body weight
- Global Phase III trials likely to start by end 2009
- IND approved by USFDA
- Glenmark takes a step closer towards becoming the first
Indian company to have a truly global innovative drug for the world
In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), 'Melogliptin', Glenmark's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight.
In this 12-week, randomized, double-blind, placebo-controlled, parallel group study, Melogliptin significantly reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.75% in patients receiving 50mg twice daily dose (p<0001) and 0.60 % in patients receiving 100 mg once daily dose (p<.0001).
In a subgroup of patients with higher baseline HbA1c of 8.5%-10%, Melogliptin reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.88 % and 1.05 % in patients receiving 100mg once daily dose and 50mg twice daily dose respectively, which compares favorably to reported results of other DPP-4's.
The Phase IIb results for Melogliptin demonstrate potential for offering
class leading improvements in glycemic control and metabolic function.
Glenmark recently received IND approval from the USFDA to carry out a
clinical study in the US. Glenmark continues to be in discussions with
various licensing partners
'/>"/>
| SOURCE Glenmark Pharmaceuticals Ltd. Copyright©2009 PR Newswire. All rights reserved |